Willem M. Smit
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments 10
- Hematopoietic Stem Cell Transplantation 6
- Immunology top 10%
- Immunotherapy and Immune Responses 5
- Oncology top 10%
- Cancer Treatment and Pharmacology 10
- Colorectal Cancer Treatments and Studies 6
- CAR-T cell therapy research 4
- Genetics top 10%
- Chronic Lymphocytic Leukemia Research 6
- Otorhinolaryngology top 10%
-
- Ovarian cancer diagnosis and treatment 7
- Co-authors
- J.H. Frederik FalkenburgRoel WillemzeCornelis A.M. van BergenWillem E. FibbeEllie G.A. LurvinkHanneke C. Kluin‐NelemansJ. E. LandegentPetra Kluck
- Cited by
- HematologyImmunologyOncology
- Journals
- Proceedings of the National Academy of Sciences (1 paper)Journal of Clinical Oncology (6 papers)Blood (3 papers)
- Partner nations
- NetherlandsUnited StatesBelgium
In The Last Decade
Willem M. Smit
36 papers receiving 908 citations
Peers
Comparison fields: 5 of 89
- Hematology 374
- Immunology 356
- Oncology 422
- Genetics 114
- Otorhinolaryngology 39
Countries citing papers authored by Willem M. Smit
This map shows the geographic impact of Willem M. Smit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willem M. Smit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willem M. Smit more than expected).
Fields of papers citing papers by Willem M. Smit
This network shows the impact of papers produced by Willem M. Smit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willem M. Smit. The network helps show where Willem M. Smit may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Willem M. Smit, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 5 | |
| 2 | 2020 | 7 | |
| 3 | 2015 | 8 | |
| 4 | 2013 | 54 | |
| 5 | 2013 | 6 | |
| 6 | 2012 | 34 | |
| 7 | 2011 | 48 | |
| 8 | 2011 | 46 | |
| 9 | 2011 | 26 | |
| 10 | A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer | 2007 | 1 |
| 11 | 2006 | 5 | |
| 12 | 2005 | 5 | |
| 13 | 2003 | 49 | |
| 14 | 2002 | 8 | |
| 15 | 2002 | 24 | |
| 16 | 1997 | 58 | |
| 17 | 1997 | 77 | |
| 18 | 1996 | 11 | |
| 19 | 1993 | 40 | |
| 20 | 1990 | 4 |
About Willem M. Smit
Willem M. Smit is a scholar working on Hematology, Reproductive Medicine and Oncology, having authored 36 papers that have together received 934 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (10 papers), Chronic Myeloid Leukemia Treatments (10 papers), Ovarian cancer diagnosis and treatment (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Colorectal Cancer Treatments and Studies (6 papers), Hematopoietic Stem Cell Transplantation (6 papers), Immunotherapy and Immune Responses (5 papers) and CAR-T cell therapy research (4 papers). The work is most often cited by research in Hematology (374 citations), Immunology (356 citations) and Oncology (422 citations). Willem M. Smit has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include J.H. Frederik Falkenburg, Roel Willemze, Cornelis A.M. van Bergen, Willem E. Fibbe, Ellie G.A. Lurvink, Hanneke C. Kluin‐Nelemans, J. E. Landegent, Petra Kluck, Amon R. Wafelman and Peter Joosten. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.